Cyberattack Disrupts Boston Scientific’s Operations: 7 Things to Know
Boston Scientific disclosed a cyberattack disrupting its global IT systems and order shipping capabilities, with the company unable to provide a timeline for when normal operations will resume. The disclosure adds the medical device giant to a growing list of medtech companies — including Stryker, Medtronic and Abbott — hit by major cyberattacks this year.
Revolution Medicines Receives Landmark FDA Drug Approval in Pancreatic Cancer
FDA approval of Revolution Medicines’ daraxonrasib, brand name Rasonque, makes the molecule the first RAS inhibitor approved for treating pancreatic adenocarcinoma, the most common type of pancreatic cancer. The speedy regulatory nod specifically covers advanced cases of this type of cancer, which has had limited treatment options.
Stop Pitching the Institute — Pitch the Stack
Health-tech pilots don't usually fail because the product is bad. They fail because the system was never wired to absorb it.
Why Oura’s Sleep-Tracking Lawsuit Is Really About Trust
A new class action lawsuit accuses Oura of overstating its smart ring's sleep tracking accuracy, arguing the device relies on AI-generated estimates rather than the clinical measurements needed for true sleep staging. The case is reigniting questions about how much precision consumers should expect from AI-powered health wearables.
Business Group on Health: Employer Healthcare Costs Projected to Rise 9.2% in 2027
Employers expect healthcare costs to rise 9.2% in 2027 as they seek ways to curb rising hospital and pharmacy costs.